Used in research as a potent and selective inhibitor of protein arginine methyltransferase 1 (PRMT1), GSK3368715 has been investigated for its potential in cancer therapy. It targets epigenetic pathways involved in tumor growth, particularly in hematological malignancies and certain solid tumors. By blocking PRMT1 activity, it affects gene expression and RNA processing, leading to cancer cell death. It has been evaluated in clinical trials to assess its efficacy and safety in patients with advanced cancers, especially those with specific genetic vulnerabilities. Its application is primarily in oncology drug development and as a tool compound for studying PRMT-dependent cellular mechanisms.